Clinical Trial Update: A Study of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors. [Phase 1, Phase 2]

View source ↗

Summary

A study evaluating ZG19018 in KRAS G12C mutant advanced solid tumors across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kras G12c Mutant Solid Tumors

Drugs mentioned

• ZG19018

Snippet

Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Conditions: KRAS G12C Mutant Advanced Solid Tumors | Phase 1, Phase 2 | Status: UNKNOWN